Celivarone

Celivarone
Names
Preferred IUPAC name
Propan-2-yl 2-butyl-3-{4-[3-(dibutylamino)propyl]benzoyl}-1-benzofuran-5-carboxylate
Other names
SSR149744C
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.211.855 Edit this at Wikidata
UNII
  • InChI=1S/C34H47NO4/c1-6-9-14-31-32(29-24-28(19-20-30(29)39-31)34(37)38-25(4)5)33(36)27-17-15-26(16-18-27)13-12-23-35(21-10-7-2)22-11-8-3/h15-20,24-25H,6-14,21-23H2,1-5H3 ☒N
    Key: ZCENNVQCOZQSGH-UHFFFAOYSA-N ☒N
  • InChI=1/C34H47NO4/c1-6-9-14-31-32(29-24-28(19-20-30(29)39-31)34(37)38-25(4)5)33(36)27-17-15-26(16-18-27)13-12-23-35(21-10-7-2)22-11-8-3/h15-20,24-25H,6-14,21-23H2,1-5H3
    Key: ZCENNVQCOZQSGH-UHFFFAOYAX
  • O=C(OC(C)C)c3cc1c(oc(c1C(=O)c2ccc(cc2)CCCN(CCCC)CCCC)CCCC)cc3
Properties
C34H47NO4
Molar mass 533.753 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Celivarone is an experimental drug being tested for use in pharmacological antiarrhythmic therapy.[1] Cardiac arrhythmia is any abnormality in the electrical activity of the heart. Arrhythmias range from mild to severe, sometimes causing symptoms like palpitations, dizziness, fainting, and even death.[2] They can manifest as slow (bradycardia) or fast (tachycardia) heart rate, and may have a regular or irregular rhythm.[2]

  1. ^ Gautier, P; Guillemare, E; Djandjighian, L; Marion, A; Planchenault, J; Bernhart, C; Herbert, JM; Nisato, D (August 2004). "In vivo and in vitro Characterization of the Novel Antiarrhythmic Agent SSR149744C: Electrophysiological, Anti-adrenergic, and Anti-angiotensin II effects". Journal of Cardiovascular Pharmacology. 44 (2): 244–57. doi:10.1097/00005344-200408000-00015. PMID 15243307. S2CID 12663630.
  2. ^ a b Hoffman, BF (September 1966). "Physiological Basis of Cardiac Arrhythmias. II". Modern Concepts of Cardiovascular Disease. 35 (9): 107–10. PMID 5945668.